ArticleDiscover oncology2025
Global bone cancer incidence and death rate analysis at 40 years.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparison of Outcomes between Prolonged Neoadjuvant Chemotherapy followed by Delayed Surgery and Immediate Surgery with Adjuvant Chemotherapy in Osteosarcoma Patients: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Review
- Antimetastatic Effects of aAntioxidants (Basel, Switzerland) · 2026Article
- Lamins' role in osteosarcoma.Frontiers in cell and developmental biology · 2026Review
- Epidemiology of bone cancer in Saudi Arabia: a nationwide population-based study (2004-2020).Frontiers in oncology · 2026Article
- Malignant and Bony Tumors of the Pediatric Hand: A Review of Diagnosis and Treatment Strategies.Cureus · 2025Review
- Neurotrophic factors as double-edged swords in osteosarcoma: drivers of tumour growth and immune remodelling.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone cancer exhibits significant global disparities in incidence and mortality. Understanding these trends is essential for identifying high-risk populations and informing targeted interventions.
methodsUsing data from the Global Burden of Disease Study 2021 (GBD 2021) and the Cancer Incidence in Five Continents (CI5) database, this study analyzed bone cancer incidence (1993-2017) and mortality (1980-2021) trends. Age-standardized incidence rates (ASRs, per 100,000) and mortality rates were assessed across regions, countries, income levels, and health systems, focusing on gender differences and healthcare capacity.
resultsBone cancer ASRs (1993-2017) ranged from 0.53 to 2.72 for females (China: Yunmeng County, 2.72 [2.16-3.28]) and 0.90-4.28 for males (China: Xiangfu District, 4.28 [3.25-5.31], p < 0.0001), with minimal rates near zero like Brazil: Jau and USA: Hawaii Chinese. Mortality rates (1980-2021) peaked in Eastern Europe and Central Asia, with male rates up to 2.90 (Romania, 2.90 [1.89-3.90], 1980) and female rates up to 2.34 (Greece, 2.34 [2.11-2.58], 1980), while high-income regions like Western Europe declined to 0.84 (males, 0.84 [0.76-0.90], 2021). By 2021, Upper Middle-Income countries (1.26 [0.85-1.62] for males) and Basic Health Systems (1.27 [0.85-1.59] for males) showed rising mortality, surpassing Advanced Health Systems (0.76 [0.71-0.81] for males), reflecting healthcare disparities. Thailand (males, 2.06 [1.18-3.01], 2021) and China saw increasing rates, unlike stable low rates in the USA (males, 0.71 [0.67-0.74], 2021).
conclusionsBone cancer incidence and mortality are heavily influenced by healthcare system capacity and socioeconomic factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.